P-279 A rare subset of well-differentiated gastro-entero-pancreatic neuroendocrine tumors with positive FDG PET/CT: Is it a sign of an aggressive disease?

نویسندگان

چکیده

Neuroendocrine tumors (NETs) are relatively rare and heterogeneous, mostly asymptomatic discovered incidentally. PET-CT is one of the gold diagnostic standards typically detects well-differentiated NETs using 68Gallium-Dotatate (Ga-PET/CT) more aggressive undifferentiated 18F-FDG (FDG-PET/CT). However, some displaying atypical high-grade features being detected on FDG-PET/CT. In this study, we aim to study role FDG-PET/CT in patients with gastro-entero-pancreatic (GEP) NETs, positive uptake A retrospective chart review all GEP cases diagnosed, from 2014 2021, at American University Beirut Medical Center was done. Patients who have low (G1) or intermediate (G2) findings were included based WHO classification Ki 67 ≤2 for grade >2-≤20 NETs. Out 36 G1 G2 NET diagnosed during that period, 9 (25%) met inclusion criteria study. Median age diagnosis 60 years, 6 (66%) males. 8 (88.9%) both Ga-PET/CT positive, while 1 (11.1%) negative. had 2 disease. All metastatic disease except patient locally advanced The tumor originated small bowels pancreas remaining 3 (33%). As initial treatment after diagnosis, received octreotide, capecitabine temozolomide, octreotide underwent surgical resection, everolimus, temozolomide Whipple procedure. 5 progression plan. FDG-PET/CT, median free survival (PFS) 40.1 months (95% CI, 15.4 – 64.9) mean PFS 36.2 23.1 49.2). these significantly lower reported literature G1/G2 negative (36.2 vs 71 months, p = 0.0162). FDG PET/CT shorter than literature. Should include prognostic score?.

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Neuroendocrine tumors of the gastro-entero-pancreatic system.

Gastro-entero-pancreatic (GEP) neuroendocrine tumors (NETs) are rare neoplasms, although their prevalence has increased substantially over the past three decades. Moreover, there has been an increased clinical recognition and characterization of these neoplasms. They show extremely variable biological behavior and clinical course. Most NETs have endocrine function and secrete peptides and neuro...

متن کامل

GEP-NETS update: a review on surgery of gastro-entero-pancreatic neuroendocrine tumors.

The incidence of neuroendocrine tumors (NETs) has increased in the last decades. Surgical treatment encompasses a panel of approaches ranging from conservative procedures to extended surgical resection. Tumor size and localization usually represent the main drivers in the choice of the most appropriate surgical resection. In the presence of small (<2 cm) and asymptomatic nonfunctioning NETs, a ...

متن کامل

Glyoxalase 1 copy number variation in patients with well differentiated gastro-entero-pancreatic neuroendocrine tumours (GEP-NET)

Background The glyoxalase-1 gene (GLO1) is a hotspot for copy-number variation (CNV) in human genomes. Increased GLO1 copy-number is associated with multidrug resistance in tumour chemotherapy, but prevalence of GLO1 CNV in gastro-entero-pancreatic neuroendocrine tumours (GEP-NET) is unknown. Methods GLO1 copy-number variation was measured in 39 patients with GEP-NET (midgut NET, n = 25; panc...

متن کامل

Molecular markers associated with response to chemotherapy in gastro-entero-pancreatic neuroendocrine tumors.

Response rates to cytotoxics in gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs) vary; recent trials demonstrated lack of objective response rates in up to 70% of patients. Identification of predictive therapeutic biomarkers would be beneficial in the treatment of GEP. Selected markers with known or suspected capability of predicting response to cytotoxics or prognosis (Ki-67, p53, mul...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: Annals of Oncology

سال: 2022

ISSN: ['0923-7534', '1569-8041']

DOI: https://doi.org/10.1016/j.annonc.2022.04.368